US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
アメリカ
USOTC
PT Vale Indonesia TBK (PK) (PTNDF) 銘柄情報

PT Vale Indonesia TBK (PK) (PTNDF)

0.3957

0.00

(0.00%)

終了 6月13日 5:00AM

PT Vale Indonesia TBK (PK) (PTNDF) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

0.3957

( - )

買値

0.2179

売値

0.3958

出来高

-

0.00 日の範囲 0.00

0.1545 52 週間の範囲 0.3957

時価総額

前日終値

0.3957

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

US$ 25,435,260

発行済株式数

10,539,784,534

配当利回り

PER

27.15

1 株当たり利益 (EPS)

0.01

歳入

1.04B

純利益

97.88M

PT Vale Indonesia Tbk, together with its subsidiaries, engages in the mining and processing of nickel in Indonesia. The company was formerly known as PT International Nickel Indonesia Tbk and changed its name to PT Vale Indonesia Tbk in September 2011. PT Vale Indonesia Tbk was incorporated in 1968 ... PT Vale Indonesia Tbk, together with its subsidiaries, engages in the mining and processing of nickel in Indonesia. The company was formerly known as PT International Nickel Indonesia Tbk and changed its name to PT Vale Indonesia Tbk in September 2011. PT Vale Indonesia Tbk was incorporated in 1968 and is headquartered in Jakarta, Indonesia. 詳細を表示

セクター

Materials

業界

Mining

ウェブサイト

www.vale.com

本社

Jakarta, Indonesia

設立

1968

PT Vale Indonesia TBK (PK) is listed in the Materials sector of the その他OTC with ticker PTNDF. The last closing price for PT Vale Indonesia TBK (PK) was US$0.40. Over the last year, PT Vale Indonesia TBK (PK) shares have traded in a share price range of US$ 0.1545 to US$ 0.3957.

PT Vale Indonesia TBK (PK) currently has 10,539,784,534 shares in issue. The market capitalisation of PT Vale Indonesia TBK (PK) is US$4.17 billion. PT Vale Indonesia TBK (PK) has a price to earnings ratio (PE ratio) of 27.15.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0.1362	52.4855491329	0.2595	0.3957	0.2595	2873	0.31141418	CS
26	0.158975	67.1559826803	0.236725	0.3957	0.1935	2226	0.34273605	CS
52	0.2412	156.116504854	0.1545	0.3957	0.1545	1439	0.32850424	CS
156	-0.03055	-7.16715542522	0.42625	0.42625	0.13975	3308	0.30863046	CS
260	0.0703	21.6041794714	0.3254	0.614	0.13975	4834	0.39744936	CS

PTNDF - Frequently Asked Questions (FAQ)

What is the current PT Vale Indonesia TBK (PK) share price?

The current share price of PT Vale Indonesia TBK (PK) is US$ 0.3957

How many PT Vale Indonesia TBK (PK) shares are in issue?

PT Vale Indonesia TBK (PK) has 10,539,784,534 shares in issue

What is the market cap of PT Vale Indonesia TBK (PK)?

The market capitalisation of PT Vale Indonesia TBK (PK) is USD 4.17B

What is the 1 year trading range for PT Vale Indonesia TBK (PK) share price?

PT Vale Indonesia TBK (PK) has traded in the range of US$ 0.1545 to US$ 0.3957 during the past year

What is the PE ratio of PT Vale Indonesia TBK (PK)?

The price to earnings ratio of PT Vale Indonesia TBK (PK) is 27.15

What is the cash to sales ratio of PT Vale Indonesia TBK (PK)?

The cash to sales ratio of PT Vale Indonesia TBK (PK) is 2.56

What is the registered address of PT Vale Indonesia TBK (PK)?

The registered address for PT Vale Indonesia TBK (PK) is Sequis Tower, Jakarta, Jakarta Raya, 12190

What is the PT Vale Indonesia TBK (PK) website address?

The website address for PT Vale Indonesia TBK (PK) is www.vale.com/indonesia

Which industry sector does PT Vale Indonesia TBK (PK) operate in?

PT Vale Indonesia TBK (PK) operates in the Mining sector

LTListener

LTListener 2分前

I am not going to pigeon hole them to specific timelines or dates. But they should have a strategy to raise awareness, improve presentation and have a professional approach to communication. They never wanted to be a penny stock and are developing an asset to potentially become the gold standard f

WebSlinger

WebSlinger 2分前

Another day….

Another week….

Another word-salad PR….

Another big, fat, juicy, KBLB nothingburger….

with a side order of lies….

https://i.imgflip.com/3bm6mk.jpg

northam43

northam43 3分前

SPX 60 min Chart. 60 min level Current Cycle Between Cycles (CCBC) 0 (Neutral). 60-E-2 (Overdue) confirmed at the close of the 5TH hour. Next possibilities: 60-S-1 (Extreme Overdue) 7399.80, 60-1 (Extreme Overdue) 7360.13, 60-E-1 7249.15 & 6TH UPRO Buy Signal.

https://investorshub.adv

northam43

northam43 4分前

SPX 60 min Chart. 60 min level Current Cycle Between Cycles (CCBC) 0 (Neutral). 60-E-2 (Overdue) confirmed at the close of the 5TH hour. Next possibilities: 60-S-1 (Extreme Overdue) 7399.80, 60-1 (Extreme Overdue) 7360.13, 60-E-1 7249.15 & 6TH UPRO Buy Signal.

https://investorshub.adv

gladeshawk

gladeshawk 5分前

I stick with my charts. HAWK

gladeshawk

gladeshawk 6分前

I follow my charts. When the chart changes I change. You have to be nimble to trade pennies. HAWK

WebSlinger

WebSlinger 6分前

*****BREAKING NEWS*****3RD DAY IN A ROW SHARE PRICE DIPS INTO 10s*****

BERKSHIRE AGENT

BERKSHIRE AGENT 7分前

Nice green close on a Friday. Time to ramp up for SUMMER MANIA soon ;)

Doc logic

Doc logic 8分前

brazen22,

Your concerns need to be dealing with how to disavow the check downs on bias done within the study. The regulators accepted or approved the SAP based on this check down on bias and JAMA Oncology published because even though mentioning possible sources of concern the check

Howell Industries

Howell Industries 9分前

Hey Lenny sell the place to a Data Centers they could at least put the water to good use.

Steady_T

Steady_T 10分前

Having an internal timeline is great.

Predicting what MHRA will do is clearly a problem.

I know you are not suggesting that NWBO predicted that the application was going to set the record for the longest, or one of the longest, applications in the history of the MHRA.

LTListener

LTListener 10分前

Or commitments on funding.

Lets goooooo!!!!!

Stonewallet

Stonewallet 11分前

Fair enough....like most OTC "investors" I definitely learned my lessons the hard way. Had a couple of good runners years ago that I held my entire position far too long. That was my mistake.

You are correct that the vast majority of pinks are pure junk and will crash at some point.

europa7

europa7 11分前

"Canary's HBAR ETF files to add staking..."

https://x.com/TokenRelations/status/2065479106527899775

"...What’s happening: On May 21, Canary Capital filed an updated prospectus for its Canary HBAR ETF, which it seeks to list on the Nasdaq. The update would permit the fun

LTListener

LTListener 11分前

Good use of AI prompts..

Probably 4 months+ after form10 and I think Respire could delay until say closer to IND.

I think folks need to spend some time conversing with AI to understand how valuable KRM-ll-81 can be and why a BP could salivate over such asset even befo

doccjc

doccjc 11分前

A little more than 3 weeks until the IDE decision. An approval will start human trials at the Mayo Clinic . IsoPet gaining traction . Over 1200% increase year over year . Let’s not forget the DCGI in India and the licensing potential of PrecisionGel .This share price won’t last . Neither will the b

surfkast

surfkast 11分前

Has nothing to do with Blag-O-Scammer.

cashclan

cashclan 12分前

Interesting

$166 ipo

And zero rhyme or reason...

Source...?

MONTI KING

MONTI KING 13分前

It could be SoftBank too.. they are looking to IPO AND ARE connected at the hip to sandbox

surfkast

surfkast 14分前

Pancreatic cancer is a death sentence. Most are found way too late. Had a friend who just passed. Had colon and then pancreatic.

jimr1717

jimr1717 14分前

🚀 NASDAQ2020’s buyout missing game,

Maxthedog

1-26-2026 ❌

jimr1717

July 27 2077

NASDAQ2020

November 5th 2021 ❌, 2022 ❌, 2023. ❌ ,2024 ❌ 2025 ❌ 2026, 2037, 2086

Luis Andros

Luis Andros 15分前

😅 Bears thought they had something here. This is ALL about the Form 7. Nothing else. They didn't file for June. 😵‍💫

While the CSE is eliminating the need for a form 7, it is not quite yet in effect. Simple oversight. Simple correction. OR ... believe what the R

leverage102

leverage102 19分前

RespireRx Pharmaceuticals Inc. is a leader in the discovery and development of medicines for the treatment of psychiatric and neurological disorders, with a focus on treatment options that address conditions affecting millions of people, but for which there are few or poor treatment options, includi

PT Vale Indonesia TBK (PK)

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。